Experience with tafamidis in a patient with transthyretin amyloidosis
S. N. Nasonova,
I. V. Zhirov,
M. M. Magomedov,
M. A. Saidova,
Yu. F. Osmolovskaya,
S. N. Tereschenko https://doi.org/10.18087/cardio.2020.3.n824
Abstract
Transthyretin amyloidosis (ATTR) is a threatening and severe genetic disease characterized by damages to organs and systems caused by a pathological protein transthyretin produced in the liver. Clinical manifestations of this disease vary from injuries of the nervous system to injuries of the cardiovascular system. Prognosis for ATTR-amyloidosis remains unfavorable. The absence of pathognomonic symptoms complicates diagnostics of this disease, which tends to simulate other conditions. At present, medicines exist, which are pathogenetic in the treatment of ATTR-amyloidosis. The article describes a clinical case of ATTR-amyloidosis with primary heart injury complicated with functional class III chronic heart failure during the tafamidis treatment.
Supporting agencies: have no conflict of interest
About the Authors
S. N. Nasonova
Federal State Budgetary Institution National Medical Cardiology Research Center of the Ministry of Health of the Russian Federation, Moscow, Russian Federation
Russian Federation
Сandidate of medical sciences, Senior Researcher, Department of Myocardial Disease and Heart Failure, Clinical Cardiology Research Institute named after A.L. Myasnikov Federal State Budgetary Institution Scientific Research Center for Cardiology of the Ministry of Health of the Russian Federation
Russian Federation
Сandidate of medical sciences, Senior Researcher, Department of Myocardial Disease and Heart Failure, Clinical Cardiology Research Institute named after A.L. Myasnikov Federal State Budgetary Institution Scientific Research Center for Cardiology of the Ministry of Health of the Russian Federation
I. V. Zhirov
Federal State Budgetary Institution National Medical Cardiology Research Center of the Ministry of Health of the Russian Federation, Moscow, Russian Federation
Federal State Budgetary Educational Institution of Continuing Professional Education Russian Medical Academy of Continuing Professional Education of the Ministry of Health of the Russian Federation, Department of Cardiology, Moscow, Russian Federation.
Russian Federation
Doctor of Medicine, Leading Researcher, Department of Myocardial Disease and Heart Failure, Clinical Cardiology Research Institute named after A.L. Myasnikov Federal State Budgetary Institution Scientific Research Center for Cardiology of the Ministry of Health of the Russian Federation, Moscow, 3rd Cherepkovskaya str.15a, 8-495-414-67-88. Professor, Department of Cardiology, Federal State Budgetary Educational Institution of Continuing Professional Education Russian Medical Academy of Continuing Professional Education of the Ministry of Health of the Russian Federation, Department of Cardiology, Russian Federation
Russian Federation
Doctor of Medicine, Leading Researcher, Department of Myocardial Disease and Heart Failure, Clinical Cardiology Research Institute named after A.L. Myasnikov Federal State Budgetary Institution Scientific Research Center for Cardiology of the Ministry of Health of the Russian Federation, Moscow, 3rd Cherepkovskaya str.15a, 8-495-414-67-88. Professor, Department of Cardiology, Federal State Budgetary Educational Institution of Continuing Professional Education Russian Medical Academy of Continuing Professional Education of the Ministry of Health of the Russian Federation, Department of Cardiology, Russian Federation
M. M. Magomedov
Federal State Budgetary Institution National Medical Cardiology Research Center of the Ministry of Health of the Russian Federation, Moscow, Russian Federation
Russian Federation
resident of the department of myocardial diseases and heart failure Research Institute of Clinical Cardiology named after A.L. Myasnikov Federal State Budgetary Institution Scientific Research Center for Cardiology of the Ministry of Health of the Russian Federation
Russian Federation
resident of the department of myocardial diseases and heart failure Research Institute of Clinical Cardiology named after A.L. Myasnikov Federal State Budgetary Institution Scientific Research Center for Cardiology of the Ministry of Health of the Russian Federation
M. A. Saidova
Federal State Budgetary Institution National Medical Cardiology Research Center of the Ministry of Health of the Russian Federation, Moscow, Russian Federation
Russian Federation
Doctor of Medicine, Professor, Head of the Department of Ultrasound Diagnostics, Clinical Cardiology Research Institute named after A.L. Myasnikov Federal State Budgetary Institution Scientific Research Center for Cardiology of the Ministry of Health of the Russian Federation
Russian Federation
Doctor of Medicine, Professor, Head of the Department of Ultrasound Diagnostics, Clinical Cardiology Research Institute named after A.L. Myasnikov Federal State Budgetary Institution Scientific Research Center for Cardiology of the Ministry of Health of the Russian Federation
Yu. F. Osmolovskaya
Federal State Budgetary Institution National Medical Cardiology Research Center of the Ministry of Health of the Russian Federation, Moscow, Russian Federation
Russian Federation
Сandidate of medical sciences, head of the department of myocardial diseases and heart failure, Clinical Cardiology Research Institute named after A.L. Myasnikov Federal State Budgetary Institution Scientific Research Center for Cardiology of the Ministry of Health of the Russian Federation
Russian Federation
Сandidate of medical sciences, head of the department of myocardial diseases and heart failure, Clinical Cardiology Research Institute named after A.L. Myasnikov Federal State Budgetary Institution Scientific Research Center for Cardiology of the Ministry of Health of the Russian Federation
S. N. Tereschenko
Federal State Budgetary Institution National Medical Cardiology Research Center of the Ministry of Health of the Russian Federation, Moscow, Russian Federation
Federal State Budgetary Educational Institution of Continuing Professional Education Russian Medical Academy of Continuing Professional Education of the Ministry of Health of the Russian Federation, Department of Cardiology, Moscow, Russian Federation.
Russian Federation
Doctor of Medical Sciences, Professor, First Deputy General Director, Deputy General Director for Scientific Research, Head of the Department of Myocardial Disease and Heart Failure, Federal State Budget Scientific Institution Cardiology of the Ministry of Health of the Russian Federation
Russian Federation
Doctor of Medical Sciences, Professor, First Deputy General Director, Deputy General Director for Scientific Research, Head of the Department of Myocardial Disease and Heart Failure, Federal State Budget Scientific Institution Cardiology of the Ministry of Health of the Russian Federation
References
1. Witteles RM, Bokhari S, Damy T, Elliott PM, Falk RH, Fine NM et al. Screening for Transthyretin Amyloid Cardiomyopathy in Everyday Practice. JACC: Heart Failure. 2019;7(8):709–16. DOI: 10.1016/j.jchf.2019.04.010
2. Rapezzi C, Riva L, Quarta CC, Perugini E, Salvi F, Longhi S et al. Gender-related risk of myocardial involvement in systemic amyloidosis. Amyloid. 2008;15(1):40–8. DOI: 10.1080/13506120701815373
3. Rameeva A.S., Rameev V.V., Moiseev S.V., Tao P.P., Kozlovskaya L.V. Amyloid heart disease: pathomorphology, diagnostic approaches and treatment options. Consilium Medicum. 2018;20(12): 15–22. [Russian: Рамеева А. С., Рамеев В. В., Моисеев С. В., Тао П. П., Козловская Л. В. Амилоидная кардиопатия: патоморфология, методы диагностики и лечения. Consilium Medicum. 2018;20(12):15–22]. DOI: 10.26442/20751753.2018.12.000020
4. Roberts JR, Lan ML. Transthyretin-Related Amyloidosis: Practice Essentials, Background, Pathophysiology. Medscape. 2018; [Av. at https://emedicine.medscape.com/article/335301-overview#a2]
5. Sun JP, Stewart WJ, Yang XS, Donnell RO, Leon AR, Felner JM et al. Differentiation of Hypertrophic Cardiomyopathy and Cardiac Amyloidosis from Other Causes of Ventricular Wall Thickening by Two-Dimensional Strain Imaging Echocardiography. The American Journal of Cardiology. 2009;103(3):411–5. DOI: 10.1016/j.amjcard.2008.09.102
6. Bhogal S, Ladia V, Sitwala P, Cook E, Bajaj K, Ramu V et al. Cardiac Amyloidosis: An Updated Review with Emphasis on Diagnosis and Future Directions. Current Problems in Cardiology. 2018;43(1): 10–34. DOI: 10.1016/j.cpcardiol.2017.04.003
Review
For citations:
Nasonova S.N., Zhirov I.V., Magomedov M.M., Saidova M.A., Osmolovskaya Yu.F., Tereschenko S.N. Experience with tafamidis in a patient with transthyretin amyloidosis. Kardiologiia. 2020;60(3):155-160. (In Russ.) https://doi.org/10.18087/cardio.2020.3.n824
Views:
1499
Email this article 
Post a Comment 
